Relevant bibliographies by topics / Bone Marrow Transplants (BMT)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Bone Marrow Transplants (BMT)'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bone Marrow Transplants (BMT).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bone Marrow Transplants (BMT)"

1

Milone, Jorge H., Juan J. Napal, Javier A. Bordone, Virginia Prates, Cecilia Garcia, Victor H. Morales, and Orlando J. Etchegoyen. "Second Neoplasm after Bone Marrow Transplant (BMT)." Blood 106, no. 11 (November 16, 2005): 5404. http://dx.doi.org/10.1182/blood.v106.11.5404.5404.

Full text
Abstract:
Abstract Introduction: the second neoplasm, are pathologies described during the post transplant evolution, often associated to immunosuppression. The post transplant lymphoproliferative syndromes, habitually associated to viruses are the most frequent. The BMT is a procedure clearly different from the rest of the transplants, and this difference would also be observed on the incidence and type of tumor in its evolution. The incidence of second malignancies after BMT is low, and is related to the use of chemotherapy, particulary alkylating. agents radiotheraphy and immunosuppression. Objective: To analyze the incidence and characteristics of second neoplasm of the patients undergoing BMT in our Institute. Results: Between 06/93 and 04/05 over a total of 416 transplants, 132 Allogenic and 284 Autologous, 6 cases of second tumor in variable intervals post procedure were stated. Table 1. The data reflects an incidence of second neoplasias of 1,4% (6/416). None of then received radiotherapy in conditioning. No lymphoproliferative syndrome was observed; 2 cases of acute leukemias; being the rest solid tumors with expected evolutions for each pathology. Table 1 Case Disease Conditioning BMT 2nd Tumor Time betwen BMT-Tumor Evolution 1 MM L-PAM AUTO Lung Cancer 120 months Dead 2 CML BuCy ALLO Colon Cancer 72 months Dead 3 MDS BuCy ALLO Merckel cells tumor 60 months Dead 4 NHL CBV AUTO AML 65 months Dead 5 NHL CBV AUTO Bladder Cancer 58 months Alive 26 months 6 NHL CBV AUTO AML 4 months Dead
APA, Harvard, Vancouver, ISO, and other styles
2

Carrigan, DR, and KK Knox. "Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6- associated bone marrow suppression in bone marrow transplant patients [see comments]." Blood 84, no. 10 (November 15, 1994): 3307–10. http://dx.doi.org/10.1182/blood.v84.10.3307.3307.

Full text
Abstract:
Abstract These studies tested the hypothesis that human herpesvirus 6 (HHV-6) can cause posttransplant bone marrow (BM) suppression in BM transplant (BMT) patients. Fifteen adult patients who received T-lymphocyte- depleted, allogeneic BM transplants and who developed posttransplant BM suppression were studied. Detailed chart reviews were used to divide the patients into two groups: (1) those with diagnosed BM suppression (DBMS) and (2) those with idiopathic BM suppression (IBMS). BM aspirates obtained from the patients at the onset of BM suppression were subjected to an HHV-6 isolation procedure using mitogen-stimulated blood mononuclear cells. BM specimens obtained from another population of BMT patients solely to document engraftment irrespective of their BM function were also subjected to the HHV-6 isolation procedure as controls. HHV-6 was isolated from 6 of 15 BM samples from BMT patients with BM suppression. BM samples from patients with IBMS were more likely to be positive for HHV-6 than those from patients with DBMS (P < .01). Also, HHV-6-positive BM were significantly more likely (P < .05) to come from patients with suppression of more than one BM lineage than HHV-6-negative BM. Finally, samples of BM from an unselected series of BMT patients studied without regard to their BM function were less likely (P < .01) to be positive for HHV-6 than patients with IBMS.
APA, Harvard, Vancouver, ISO, and other styles
3

Carrigan, DR, and KK Knox. "Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6- associated bone marrow suppression in bone marrow transplant patients [see comments]." Blood 84, no. 10 (November 15, 1994): 3307–10. http://dx.doi.org/10.1182/blood.v84.10.3307.bloodjournal84103307.

Full text
Abstract:
These studies tested the hypothesis that human herpesvirus 6 (HHV-6) can cause posttransplant bone marrow (BM) suppression in BM transplant (BMT) patients. Fifteen adult patients who received T-lymphocyte- depleted, allogeneic BM transplants and who developed posttransplant BM suppression were studied. Detailed chart reviews were used to divide the patients into two groups: (1) those with diagnosed BM suppression (DBMS) and (2) those with idiopathic BM suppression (IBMS). BM aspirates obtained from the patients at the onset of BM suppression were subjected to an HHV-6 isolation procedure using mitogen-stimulated blood mononuclear cells. BM specimens obtained from another population of BMT patients solely to document engraftment irrespective of their BM function were also subjected to the HHV-6 isolation procedure as controls. HHV-6 was isolated from 6 of 15 BM samples from BMT patients with BM suppression. BM samples from patients with IBMS were more likely to be positive for HHV-6 than those from patients with DBMS (P < .01). Also, HHV-6-positive BM were significantly more likely (P < .05) to come from patients with suppression of more than one BM lineage than HHV-6-negative BM. Finally, samples of BM from an unselected series of BMT patients studied without regard to their BM function were less likely (P < .01) to be positive for HHV-6 than patients with IBMS.
APA, Harvard, Vancouver, ISO, and other styles
4

Jones, RJ, RF Ambinder, S. Piantadosi, and GW Santos. "Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation." Blood 77, no. 3 (February 1, 1991): 649–53. http://dx.doi.org/10.1182/blood.v77.3.649.649.

Full text
Abstract:
Abstract The existence of an immunologic antileukemia reaction associated with allogeneic bone marrow transplantation (BMT) is well established. However, a similar graft-versus-tumor effect against lymphomas has not been demonstrated. We analyzed the results of BMT in 118 consecutive patients with relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma. The 38 patients less than 50 years of age with HLA-matched donors had allogenic marrow transplants, and the other 80 patients received purged autologous grafts. The median age was 26 years in both the allogeneic and the autologous graft recipients. The patient's response to conventional salvage therapy before transplant was the only factor that influenced the event-free survival after BMT (P less than .001). Both the patient's response to salvage therapy before BMT (P less than .001) and the type of graft (P = .02) significantly influenced the probability of relapse after BMT. The actuarial probability of relapse in patients who responded to conventional salvage therapy before BMT was only 18% after allogenic BMT compared with 46% after autologous BMT. However, the actuarial probability of event-free survival at 4 years was the same, 47% versus 41%, for patients with responsive lymphomas who received allogeneic and autologous transplants, respectively (P = .8). The beneficial antitumor effect of allogeneic BMT was offset by its higher transplant-related mortality (P = .01), largely resulting from graft-versus-host disease. Allogeneic BMT appears to induce a clinically significant graft-versus- lymphoma effect. The magnitude of this effect is similar to that reported against leukemias.
APA, Harvard, Vancouver, ISO, and other styles
5

Jones, RJ, RF Ambinder, S. Piantadosi, and GW Santos. "Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation." Blood 77, no. 3 (February 1, 1991): 649–53. http://dx.doi.org/10.1182/blood.v77.3.649.bloodjournal773649.

Full text
Abstract:
The existence of an immunologic antileukemia reaction associated with allogeneic bone marrow transplantation (BMT) is well established. However, a similar graft-versus-tumor effect against lymphomas has not been demonstrated. We analyzed the results of BMT in 118 consecutive patients with relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma. The 38 patients less than 50 years of age with HLA-matched donors had allogenic marrow transplants, and the other 80 patients received purged autologous grafts. The median age was 26 years in both the allogeneic and the autologous graft recipients. The patient's response to conventional salvage therapy before transplant was the only factor that influenced the event-free survival after BMT (P less than .001). Both the patient's response to salvage therapy before BMT (P less than .001) and the type of graft (P = .02) significantly influenced the probability of relapse after BMT. The actuarial probability of relapse in patients who responded to conventional salvage therapy before BMT was only 18% after allogenic BMT compared with 46% after autologous BMT. However, the actuarial probability of event-free survival at 4 years was the same, 47% versus 41%, for patients with responsive lymphomas who received allogeneic and autologous transplants, respectively (P = .8). The beneficial antitumor effect of allogeneic BMT was offset by its higher transplant-related mortality (P = .01), largely resulting from graft-versus-host disease. Allogeneic BMT appears to induce a clinically significant graft-versus- lymphoma effect. The magnitude of this effect is similar to that reported against leukemias.
APA, Harvard, Vancouver, ISO, and other styles
6

Grovas, Alfred, Stephen A. Feig, Sheryl O'rourke, Leonard Valentino, Fran Wiley, Lynne Hunt, Elliot M. Landaw, and James Gajewski. "Unrelated Donor Bone Marrow Transplants in Children." Cell Transplantation 3, no. 5 (September 1994): 413–20. http://dx.doi.org/10.1177/096368979400300508.

Full text
Abstract:
Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling. To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed. We report the outcome of 24 consecutive unrelated donor BMT's performed on children. Eligible diagnosis included acute leukemia (AL) (n = 15), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), and severe aplastic anemia (SAA) (n = 2). All donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens. Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients. All recipients received graft-versus-host-disease (GVHD) prophylaxis with cyclosporine-A (CSA), four with short course methotrexate (MTX), 14 in combination with short course MTX and methylprednisolone (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65). One patient received CSA and MPS alone after a T-cell depleted marrow transplant. Twenty of 23 evaluable recipients engrafted (87%). Two patients with CML never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early death at day + 9. Fourteen of 20 patients (70%) with stable donor-derived hematopoiesis developed significant acute GVHD ≥ grade II). Eleven of 15 engrafted patients who survived > 100 days after BMT developed chronic GVHD (73%). Thirteen patients survive, 10 disease-free; 2 yr actuarial survival and disease-free survival are 47% and 41%, respectively. Of the 19 engrafted patients with leukemia or MDS, only three have relapsed. The actuarial relapse risk at 2 yr is 24%. Unrelated donor transplants in children are associated with an increased risk of GVHD and nonengraftment compared to matched sibling transplants. Increased donor age is significantly associated with a greater risk of acute GVHD.
APA, Harvard, Vancouver, ISO, and other styles
7

Gahrton, G., S. Tura, P. Ljungman, J. Bladé, L. Brandt, M. Cavo, T. Façon, A. Gratwohl, A. Hagenbeek, and P. Jacobs. "Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma." Journal of Clinical Oncology 13, no. 6 (June 1995): 1312–22. http://dx.doi.org/10.1200/jco.1995.13.6.1312.

Full text
Abstract:
PURPOSE To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. PATIENTS AND METHODS One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. RESULTS Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta 2-microglobulin level (< 4 g/L) also tended to have a favorable prognostic impact. The most important post-transplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. CONCLUSION Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
APA, Harvard, Vancouver, ISO, and other styles
8

Demagalhaes-Silverman, Margarida, Albert D. Donnenberg, Steven M. Pincus, and Edward D. Ball. "Bone Marrow Transplantation: A Review." Cell Transplantation 2, no. 1 (January 1993): 75–98. http://dx.doi.org/10.1177/096368979300200110.

Full text
Abstract:
The indications for bone marrow transplantation (BMT) continue to expand as supportive care improves and alternative stem cell sources have been exploited. The application of allogeneic BMT has expanded to include unrelated histocompatibility antigen-matched donors and partially matched family donors. While the results of these transplants are not as good as those with sibling donors, these alternative donors allow curative therapy to be delivered to patients with leukemia, aplastic anemia, and immunodeficiency diseases who otherwise would not be eligible for curative therapy. Autologous BMT has emerged as a curative therapy for patients with non-Hodgkin's lymphoma, Hodgkin's disease, acute myeloid leukemia, and acute lymphoblastic leukemia. In addition, dose-intensive therapy with marrow or peripheral blood stem cell support to patients with Stage II, III, and IV breast carcinoma is under intense study in single and multiple-institution studies. Important issues under active study are prophylaxis for graft-versus-host-disease, the role of marrow purging in autologous BMT, the use of cytokine and chemotherapy-mobilized peripheral blood stem cells, and control of infectious diseases. This review summarizes current results in both allogeneic and autologous bone marrow transplantation, issues in marrow graft manipulations, issues in infectious disease control, the application of gene therapy to correct genetic disease through bone marrow or peripheral blood infusion, and current concepts in post-BMT immunization.
APA, Harvard, Vancouver, ISO, and other styles
9

Barrett, AJ, MM Horowitz, RP Gale, JC Biggs, BM Camitta, KA Dicke, E. Gluckman, RA Good, RH Herzig, and MB Lee. "Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival." Blood 74, no. 2 (August 1, 1989): 862–71. http://dx.doi.org/10.1182/blood.v74.2.862.862.

Full text
Abstract:
Abstract Transplant outcome was analyzed in 690 recipients of bone marrow transplants (BMTs) for acute lymphoblastic leukemia (ALL) in first (n = 299) or second remission (n = 391). Actuarial 5-year leukemia-free survival was 42% +/- 9% (95% confidence interval) and 26% +/- 6%, respectively; relapse rates were 29% +/- 9% and 52% +/- 8%, respectively. Five-year leukemia-free survival was 56% +/- 18% in children and 39% +/- 10% in adults (P less than .02) transplanted in first remission. In first-remission adults, non-T-cell phenotype, male to female donor-recipient sex-match and graft-v-host disease (GVHD) were associated with decreased leukemia-free survival; inclusion of corticosteroids in the regimen to prevent GVHD was associated with increased leukemia-free survival. Variables associated with decreased leukemia-free survival after second-remission transplants were age greater than or equal to 16 years and relapse occurring while on therapy. Variables associated with increased probability of relapse were similar for first- and second-remission transplants and included GVHD prophylaxis without methotrexate and absence of GVHD. In first- remission transplants, leukocyte count greater than or equal to 50 x 10(9)/L at diagnosis was also associated with increased relapse; in second remission, relapse while receiving chemotherapy was also associated with increased posttransplant relapse. These data emphasize the importance of both disease- and transplant-related variables in predicting outcome after BMT. They may be used to explain differences between studies, design future trials, and identify persons most likely to benefit from BMT.
APA, Harvard, Vancouver, ISO, and other styles
10

Barrett, AJ, MM Horowitz, RP Gale, JC Biggs, BM Camitta, KA Dicke, E. Gluckman, RA Good, RH Herzig, and MB Lee. "Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival." Blood 74, no. 2 (August 1, 1989): 862–71. http://dx.doi.org/10.1182/blood.v74.2.862.bloodjournal742862.

Full text
Abstract:
Transplant outcome was analyzed in 690 recipients of bone marrow transplants (BMTs) for acute lymphoblastic leukemia (ALL) in first (n = 299) or second remission (n = 391). Actuarial 5-year leukemia-free survival was 42% +/- 9% (95% confidence interval) and 26% +/- 6%, respectively; relapse rates were 29% +/- 9% and 52% +/- 8%, respectively. Five-year leukemia-free survival was 56% +/- 18% in children and 39% +/- 10% in adults (P less than .02) transplanted in first remission. In first-remission adults, non-T-cell phenotype, male to female donor-recipient sex-match and graft-v-host disease (GVHD) were associated with decreased leukemia-free survival; inclusion of corticosteroids in the regimen to prevent GVHD was associated with increased leukemia-free survival. Variables associated with decreased leukemia-free survival after second-remission transplants were age greater than or equal to 16 years and relapse occurring while on therapy. Variables associated with increased probability of relapse were similar for first- and second-remission transplants and included GVHD prophylaxis without methotrexate and absence of GVHD. In first- remission transplants, leukocyte count greater than or equal to 50 x 10(9)/L at diagnosis was also associated with increased relapse; in second remission, relapse while receiving chemotherapy was also associated with increased posttransplant relapse. These data emphasize the importance of both disease- and transplant-related variables in predicting outcome after BMT. They may be used to explain differences between studies, design future trials, and identify persons most likely to benefit from BMT.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bone Marrow Transplants (BMT)"

1

Nikolich‐Zugich, Tijana. "Effects of High Vs. Reduced‐Dose Melphalan For Autologous Bone Marrow Transplantation in Multiple Myeloma On Pulmonary Function: A Longitudinal Study." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623514.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
Bone marrow transplants (BMT, also hematopoietic stem cell transplants or HSCT/SCT) are one of the greatest medical achievements of the 20th century. They offer a treatment for a host of malignant and nonmalignant hematopoietic disorders, genetic diseases and solid tumors that could otherwise be fatal. Studies have found that 60% of patients undergoing BMT develop pulmonary complications (PC), and 1/3 of those require intensive care after transplantation. Despite the potential pneumotoxicity of induction agents, to date there have been no longitudinal studies following pulmonary function in this high‐risk patient population. This study reviewed patient who underwent autogeneic bone marrow transplant for multiple myeloma at Banner University Medical Center – Tucson (formerly University of Arizona Health Network) from January 1, 2003 through December 31, 2013. Pretransplant evaluatin and pulmonary function testing data were obtained and stratified between high dose (standard) Melphalan (200 mg/ms2) and reduced dose (140 mg/ms2). Statistically significant differences were present between the 2 groups at baseline for DLCO but disappeared at 6 and 12‐month followup, while a statistically significant difference for FEV1/FVC ratio was seen at baseline and 6 months but disappeared at 12‐month follow‐up. There were no statistically significant differences seen with FEV1 between the two groups. Given there is no difference in mortality and relapse outcomes between the groups, the standard of care dosing for Melphalan is not associated with an increase in pulmonary morbidity.
APA, Harvard, Vancouver, ISO, and other styles
2

Ballard, Erin Elissa. "Imatinib as a Dominant Therapeutic Strategy in the Treatment of Chronic Myelogenous Leukemia: A Decision-Analytic Approach." The University of Arizona, 2004. http://hdl.handle.net/10150/624778.

Full text
Abstract:
Class of 2004 Abstract
Objective: To develop and populate a decision-analytic model comparing the cost and efficacy of imatinib versus allogenic bone marrow transplantation (BMT) with a matched unrelated donor in the treatment of newly-diagnosed, Philadelphia positive (Ph (+)), chronic phase, chronic myelogenous leukemia (CML). Design: Markov cohort analysis and Monte Carlo microsimulation. Measurements and Main Results: Direct medical costs were measured from the perspective of a third-party payer. Efficacy data and probabilities were obtained from survivability findings emanating primarily from randomized controlled trials (RCTs). A two-year time horizon was employed with three month treatment cycles. BMT was established as the baseline comparator and the base case was defined as a 35 year old, Ph(+) male patient with newly-diagnosed CML. Results from the Monte Carlo trial found that the incremental cost-efficacy ratio was −$5,000 for imatinib (95th % Confidence Interval: −$70,000, $84,000). Analysis of the cost-efficacy plane indicated that imatinib dominated BMT in 84.69 percent of cases, while BMT was dominant in 0.76 percent of cases. Sensitivity analyses of costs and discount rates found results to be robust. Conclusion: Imatinib was observed in a majority of cases to be both less costly and more efficacious relative to BMT in the treatment of CML, suggesting that this pharmaceutical agent is a dominant therapeutic strategy. When available, the incorporation of long-term clinical data are required to assess cost-efficacy beyond the two-year time horizon of this study.
APA, Harvard, Vancouver, ISO, and other styles
3

Skucek, E. "Social competence and executive function in children treated with Bone Marrow Transplant (BMT) for congenital immunodeficiency." Thesis, University College London (University of London), 2008. http://discovery.ucl.ac.uk/1445853/.

Full text
Abstract:
Significant progress in medical techniques over the past 40 years has resulted in the increased survival rate for chronically ill children and adolescents treated with Bone Marrow Transplant (BMT). Concurrent with these medical advances, research has emerged investigating the long-term psychological outcome for paediatric BMT survivors. From these studies it is possible to learn a great deal about the cognitive and psychosocial functioning of children and adolescents treated with BMT and their families. The field has progressed from descriptive studies of adjustment to more explanatory research. It is an apt time for a review of the progress made, the current state of research in this field and the perspectives on future directions.
APA, Harvard, Vancouver, ISO, and other styles
4

Poggioli, Michael. "Trait Mindfulness: A Protective Factor for Bone Marrow Transplant Recipients?" Xavier University Psychology / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=xavier1586994569736228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Daignault, Julie. "The design, development and formative evaluation of a multimedia-based pediatric patient education package : The BMT voyage : all you need to know about your bone marrow transplant." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0002/MQ39911.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lauar, Lara Zupelli. "Controle tardio da inflamação em esclerose múltipla em pacientes tratados com transplante autólogo de células tronco hematopoiéticas." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/17/17158/tde-18042018-113057/.

Full text
Abstract:
A esclerose múltipla (EM) é uma doença desmielinizante inflamatória crônica recorrente, restrita ao sistema nervoso central (SNC), cuja característica histológica é a ocorrência de desmielinização relacionada com infiltrado inflamatório perivenular com relativa preservação axonal. A forma clássica da doença se caracteriza pela recorrência de ataques (surtos), seguidos de remissão dos sintomas (RRMS), com a presença de múltiplas lesões focais dispersas pelo SNC (dissociação espacial) com processo inflamatório exuberante na fase aguda, coexistindo com lesões crônicas (dissociação temporal) sem atividade inflamatória evidenciavel pela quebra de barreira hematoencefálica e realce na fase contrastada na imagem de ressonância magnética (MRI). Alguns pacientes tem uma evolução benigna, permanecendo livre de sequelas significativas por mais de 20 anos da doença. Outros pacientes têm uma forma agressiva da doença, ficando restritos à cadeira de rodas em 8 a 10 anos de evolução. Um desafio é modificar o curso desta forma agressiva, o que pode ser feito com o uso de imunomoduladores, quimioterápicos e, eventualmente, transplante autólogo de células tronco hematopoiéticas (aHSCT). O objetivo da utilização do aHSCT é a restauração da atividade imunológica livre dos ataques à mielina (\"autoimune reset\"). Uma das maneiras de se monitorar a eficácia do tratamento é a identificação da ocorrência de novas lesões e de lesões com reforço visíveis em exames de RM seriados. Objetivo: Testar a hipótese de que o tratamento de pacientes com EM, utilizando AHSCT, foi eficaz em evitar a recorrência de inflamação e o aparecimento de novas lesões visíveis na SB ao exame de MRI, a longo prazo. Resultados: Na nossa Instituição, cerca de 66 pacientes portadores de EM foram tratados com aHSCT no período de 2004 a 2011, sendo seguidos desde então pelas disciplinas de hematologia, neurologia/neuroimunologia e pela seção de RM do CCIFM-HCRP. Método: Foram revisados os exames de RM de encéfalo adquiridos de maneira prospectiva e protocolada, de 76 pacientes submetidos ao aHSCT, com seguimento por MRI há mais de cinco anos. As imagens de RM foram arquivadas nos servidores do CCIFM, foram recuperadas, anonimizadas e revistas por pelo menos dois radiologistas experientes, de maneira independente e por confrontação. Foi considerada falha terapêutica a identificação de lesões novas e/ou lesões com reativação inflamatória. Resultados: Dez pacientes foram excluídos. Doze pacientes (18,18%) apresentaram novas lesões ou recorrência do processo inflamatório, com reforço. Conclusão: Na nossa amostra o aHSCT foi capaz de controlar a recorrência de lesões e da atividade inflamatória perceptível na RM em mais de 87% dos casos, caracterizando uma importante opção terapêutica de segunda linha nos casos de maior agressividade da doença
Multiple sclerosis (MS) is a recurrent chronic inflammatory demyelinating disease, restricted to the central nervous system (CNS), whose histological feature is the occurrence of perivenular inflammatory infiltrate, leading to demyelination with relative axonal preservation. The classic form of the disease is characterized by the recurrence of attacks (outbreaks), followed by remission of symptoms (RRMS), with the presence of multiple focal lesions dispersed by the CNS (spatial dissociation) with exuberant inflammatory process in the acute phase, coexisting with chronic lesions (Temporal dissociation) without inflammatory activity evidenced by the breakdown of blood-brain barrier and contrast-enhanced contrast-enhanced magnetic resonance imaging (MRI). Some patients have a benign course, remaining free of significant sequelae for more than 20 years of the disease. Other patients have an aggressive form of the disease, being restricted to the wheelchair in 8 to 10 years of evolution. One challenge is to modify the course in this aggressive way, which can be done with the use of immunomodulators, chemotherapeutics and, eventually, autologous hematopoietic stem cell transplantation (aHSCT). The goal of using aHSCT is to restore immune activity free of myelin attacks (\"autoimmune reset\"). One of the ways to monitor treatment efficacy is to identify the occurrence of new lesions and visible reinforcing lesions on serial MRI scans. Objective: To test the hypothesis that the treatment of patients with MS using AHSCT was effective in avoiding the recurrence of inflammation and the appearance of new visible lesions in SB at the long-term examination of MRI. Results: At our institution, approximately 66 patients with MS were treated with aHSCT from 2004 to 2011, followed by the hematology, neurology / neuroimmunology and MRI sections of the CCIFM-HCRP. Methods: Brain and MRI scans acquired in a prospective and protocolized way from 76 patients who underwent aHSCT were followed up with MRI for more than five years. The MR images were archived on the CCIFM servers, retrieved, anonymised and reviewed by at least two experienced radiologists, independently and by confrontation. The identification of new lesions and / or lesions with inflammatory reactivation was considered therapeutic failure. Results: Ten patients were excluded. Twelve patients (18.18%) presented new lesions or recurrence of the inflammatory process, with reinforcement. Conclusion: In our sample, aHSCT was able to control the recurrence of lesions and the inflammatory activity detected in MRI in more than 87% of the cases, characterizing an important second line therapeutic option in the cases of greater aggressiveness of the disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Pursall, Marieangela Caroline. "The role of DNA conformational analyses and other non-probe typing methods in the selection of HLA class I matched unrelated donors." Thesis, University of Bristol, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296689.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pap, Stephen A. "Immunomagnetic and pharmacologic purging of tumor-involved bone marrow for patients undergoing regimens of high-dose chemotherapy and autologous bone marrow support." Thesis, Boston University, 1992. https://hdl.handle.net/2144/34652.

Full text
Abstract:
Thesis (M.A.)--Boston University
PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
Autologous Bone Marrow Transplantation (ABMT) provides a way to rescue the hematopoietic system in patients receiving high dose chemotherapy. Solid tumors like lung and breast cancer are the targets for new therapies that involve high dose chemotherapy with AMBT due to their growth and pathologic characteristics. Reinfusion of bone marrow with metastatic neoplastic cells could also seed viable tumor cells, and thus be a reason for treatment failure, restricting high-dose chemotherapy with bone marrow support to patients whose marrow is morphologically free of tumor cells. The use magnetic beads for physical separation of tumor from normal cells and the use of a toxin delivered by a monoclonal antibody are examined as two purging methods for treatment. The use of magnetic beads conjugated with specific antibodies (SM1, LAM2 and LS1) against tumor antigens to purge 2-3 logs of Small Cell Lung Cancer (SCLC) contamination from bone marrow is demonstrated. Optimal performance calls for short double exposure to anti-tumor cell-antigen monoclonal antibodies, followed by exposure to magnetic beads coated with antibodies specific for the monoclonal anti-SCLC antibodies, maintaining a bead-to-cell ratio of 10:1 to 100:1. Specific toxin delivery to three breast cancer cell lines (ZR-75, BT20 and MCF7) expressing the DF3 antigen was demonstrated by the use of DF3 immunotoxin (DF3-IT). The optimal concentration of the DF3-IT immunotoxin for highest tumor kill was shown to be 1x1Q-9 M, but this caused a loss of bone marrow progenitor cell colonies of about 30%. Both methods are limited chiefly by the level of antigen expression in the target tumor cells. The purging efficiency could be improved by targeting a wider range of antigens or by inducing higher levels of antigen expression. From the clinical perspective, the advantages and need for purging involved bone marrow to bring about substantially improved curative strategies remains a question still unanswered.
2031-01-01
APA, Harvard, Vancouver, ISO, and other styles
9

Barroquillo, Ashley D. "Trajectory of Distress for Bone Marrow Transplant Inpatients and Validation of Jewish Hospital BMTU Distress Screening Measure." Xavier University / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=xavier151024883287562.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Salif, Harouna. "Effect of CDDO-me on myelopoiesis in naïve mice and in mice undergoing bone marrow transplantation (BMT)." abstract and full text PDF (UNR users only), 2009. http://0-gateway.proquest.com.innopac.library.unr.edu/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:1472976.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bone Marrow Transplants (BMT)"

1

The BMT data book: A manual for bone marrow and blood stem cell transplantation. Cambridge [England]: Cambridge University Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

S, Tallman Martin, and Stiff Patrick J, eds. Bone marrow transplants: A book of basics for patients. Highland Park, Ill: Bone & Marrow Transplant Newsletter, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shaffer, Marianne L. Bone marrow transplants: A guide for cancer patients and their families. Dallas, Tex: Taylor Pub. Co., 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Handelsman, Harry. Allogenic bone marrow transplantation (BMT) for indications other than aplastic anemia and leukemia. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Office of the Assistant Secreatary for Health, National Center for Health Services Research and Health Care Technology Assessment, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blood and circulatory disorders sourcebook: Basic consumer health information about blood and circulatory system disorders, such as anemia, leukemia, lymphoma, rh disease, hemophilia, thrombophilia, other bleeding and clotting deficiencies, and artery, vascular, and venous diseases, including facts about blood types, blood donation, bone marrow and stem cell transplants, tests and medications, and tips for maintaining circulatory health; along with a glossary of related terms and a list of resources for additional help and information. 3rd ed. Detroit: Omnigraphics, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Picoult, Jodi. My sister's keeper: A novel. New York: Atria, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Picoult, Jodi. Zi zi de shou hu zhe =: My sister's keeper. 8th ed. Taibei Shi: Taiwan shang wu yin shu guan gu fen you xian gong si, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Picoult, Jodi. My sister's keeper: A novel. New York: Atria Books, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

The BMT data book. 2nd ed. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Hassan Al-Sader. Haematopoietic stem cell transplantation. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0009.

Full text
Abstract:
Haemopoietic stem cell transplantation (SCT) - Indications for haemopoietic SCT - Allogeneic SCT - Autologous STC - Investigations for BMT/PBSCT - Pretransplant investigation of donors - Bone marrow harvesting - Peripheral blood stem cell mobilization and harvesting - Microbiological screening for stem cell cryopreservation - Stem cell transplant conditioning regimens - Infusion of cryopreserved stem cells - Infusion of fresh non-cryopreserved stem cells - Blood product support for SCT - Graft-versus-host disease (GvHD) prophylaxis - Acute GvHD - Chronic GvHD - Veno-occlusive disease (syn. sinusoidal obstruction syndrome) - Invasive fungal infections and antifungal therapy - CMV prophylaxis and treatment - Post-transplant vaccination programme and foreign travel - Longer term effect post-transplant - Treatment of relapse post-allogeneic SCT - Discharge and follow-up
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Bone Marrow Transplants (BMT)"

1

McClain, K., H. Chen, A. Filipovich, A. Feller, and G. Bornkam. "Characterization of Cell Types and EBV Gene Expression in Lymphoproliferative Diseases (LPD) of Patients Receiving Bone Marrow Transplants (BMT) after T-Cell Depletion." In Epstein-Barr Virus and Human Disease • 1988, 293–96. Totowa, NJ: Humana Press, 1989. http://dx.doi.org/10.1007/978-1-4612-4508-7_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barrett, A. J., and J. De Koning. "Bone marrow transplantation (BMT)." In Supportive therapy in haematology, 245–56. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2577-2_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ikehara, Susumu. "The Prospects for BMT — from Mouse to Human." In Bone Marrow Transplantation, 302–31. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-68320-9_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hansen, John A., Jorge Sierra, Effie W. Petersdorf, Paul J. Martin, and Claudio Anasetti. "Hematopoietic Stem Cell Transplants from Unrelated Donors." In Bone Marrow Transplantation, 233–45. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-68320-9_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fregatova, L., G. Platonova, O. Volkova, S. Shawa, and B. Afanasiev. "Transfusion problems of allogenic bone marrow transplantation (BMT)." In Gene Technology, 537–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-61122-3_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Feldman, S. "Varicella Zoster Infections in Bone Marrow Transplants." In Infectious Complications in Bone Marrow Transplantation, 175–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84899-5_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bordigoni, P., M. Marchand, F. Witz, and D. Olive. "Functions of Monocytes after Allogeneic Bone-Marrow Transplantation (BMT)." In 11th Annual meeting of the EBMT, 94. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-662-40457-7_73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kalaycio, Matt E. "What Is the Curative Potential of Refractory Leukemia with Related and Unrelated Allogeneic Transplants?" In Current Controversies in Bone Marrow Transplantation, 107–17. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-657-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Santos, G. W., A. M. Yeager, R. Saral, W. H. Burns, J. R. Wingard, R. Jones, R. F. Ambinder, et al. "Allogeneic and Autologous Marrow Transplants in Acute Nonlymphoblastic Leukemia (ANLL)." In Recent Advances and Future Directions in Bone Marrow Transplantation, 74–81. New York, NY: Springer New York, 1988. http://dx.doi.org/10.1007/978-1-4612-3762-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patterson, J., H. G. Prentice, M. Gilmore, H. Blacklock, M. K. Brenner, G. Janossy, D. Skeggs, et al. "Analysis of Rejection in HLA Matched T-Depleted Bone Marrow Transplants." In 11th Annual meeting of the EBMT, 117. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-662-40457-7_93.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bone Marrow Transplants (BMT)"

1

Ryan, K., N. Shah, S. Holland, K. Olivier, D. Hickstein, H. J. Ford III, and N. A. Weir. "Resolution of Pulmonary Arterial Hypertension (PAH) in a Patient with GATA-2 Deficiency Following Bone Marrow Transplant (BMT)." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Szabolcs, P., X. Chen, A. Donnenberg, S. Mcintyre, M. Mangiola, J. Barnum, J. F. McDyer, and G. Kurland. "In Vitro Analysis of Alloreactivity and Tolerance in Bilateral Orthotopic Lung Transplant (BOLT) in Tandem with Bone Marrow Transplant (BMT) Recipients." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gowdy, Kymberly, Julia L. Nugent, Laurie D. Snyder, Tereza Martinu, and Scott M. Palmer. "LPS Potentiates Th17 And Th2 Mediated Chronic Pulmonary Graft-Versus-Host Disease (GVHD) After Allogeneic Bone Marrow Transplant (BMT)." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fitzpatrick, Frances, James Evans, and Gemma Renshaw. "89 A service evaluation of snack availability for bone marrow transplant (BMT) & immunology inpatients at great ormond street hospital (GOSH)." In GOSH Conference 2019, Care of the Complex Child. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-gosh.89.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tirindelli, M. C., W. Arcese, G. Mariani, G. Papa, C. Fossati, and G. Iacopino. "EVALUATION OF CLOTTING PARAMETERS AND PHYSIOLOGICAL INHIBITORS IN PH /+ CHRONIC MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643211.

Full text
Abstract:
The aim of this study is to evaluate blood coagulation changes in Ph positive chronic myeloid leukemia (Ph + CML) patients undergoing allogeneic bone marrow transplantation (BMT), T-depleted with the monoclonal antibody Campath 1, and to find a possible correlation between changes of procoagulant proteins, physiological inhibitors and venoclusive disease (VOD). VOD is a major complication in, the early period following BMT.Out of 13 patients, two of them developed VOD. Von Willebrand Factor Antigen (vWF:Ag), Factor VII antigen (F.VII:Ag), Plasminogen antigen (PLG:Ag), Factor V activity (F.V:C), Antithrombin III activity, Protein C antigen (PC:Ag) and fibrinogen activity (FG) were evaluated in all patients following sampling times: day 10 (before conditioning regimen), day 0 (day of BMT), day + 10 (after BMT), day + 28 (median day of engraftment) and day + 60 (after BMT).PLG:Ag, F. VII:Ag and PC:Ag levels decreased significantly (p values < .05, < .025, < .001 respectively). In particular, in 5 patients whose PC:Ag levels dropped below the limit considered at risk for thrombosis (< 60 U/dl), two of them developed VOD. vWF:Ag, F. V:C and FG increased significantly (p values < .04, < .05, < .05 respectively). Antithrombin III activity did not change significantly throughout the period of observation.In conclusion, the reduction of PC, PLG and the contemporary rise of vWF and FG can increase the risk of developing thromboembolism in the early stage following BMT.
APA, Harvard, Vancouver, ISO, and other styles
6

Moammar, MQ, YJ Khelfa, FA Chaudry, T. Refaie, and MA Khan. "Significance of Pulmonary Function Changes after Bone Marrow Transplantation (BMT) in Predicting Mortality." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

CARON, C., J. P. JOUET, J. HIMPENS, P. HIVES, H. GRUSON, and J. GOUDEMAND. "MODERATE DECREASE OF FACTOR VII AND PROTEIN C WITHOUT OCCURRENCE OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN 18 PATIENTS TREATED WITH LOW DOSE HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644337.

Full text
Abstract:
Decrease of factor VII (F VII) and protein C (PC) has been said to allow an early detection of hepatic veno-occlusive disease (VOD) (VILMER, Path. Biol. 1986, 34 : 79), that represents a serious complication of bone marrow transplantation (BMT). In this purpose, F VII (activity) and PC (antigen) have been measured in 18 patients (aged 9 to 45 yr- m : 26 yr) who underwent allogeneic bone marrow graft for chronic myelogenous leukemia (9 cases), acute lymphocytic leukemia (7 cases) acute myelogenous leukemia (2 cases). All patients received as preparation for BMT total body irradiation (mean dose = 10 Gy) along with cyclophosphamide (120 mg/Kg). All were given low dose heparin (100 UI/Kg/24 hr) from days -7 to +30. None of the patients developed VOD but graft-versus-host disease occurred in 13 out of them between days 18 and 52. Moreover, coagulation studies performed from days 1 to 28 detected a moderate decrease of F VII and PC (maximum on day 11). These parameters were normalized on day 28. The level of the other vitamin K-dependent factors was not significantly changed.So the moderate decrease of F VII and PC found in the post-graft period was not associated with hepatic VOD. However, as none of the patients developed this complication, these results do not exclude that a major decrease of these parameters could serve as an early diagnosis of VOD. On the other hand, a prophylactic effect of low dose heparin cannot be ruled out.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bone Marrow Transplants (BMT)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography